Normalized Pre-Tax Income: A company's income before income tax expense smoothed out by removing non-recurring items.
Jasper Therapeutics, Inc. (JSPR) had Normalized Pre-Tax Income of $-2.76M for the most recently reported fiscal quarter, ending 2026-06-30.
| Income Statement Financials | |
-- |
|
$-2.76M |
|
-- |
|
-- |
|
$9.21M |
|
$-9.21M |
|
$6.45M |
|
$-2.76M |
|
|
Normalized Pre-Tax Income |
$-2.76M |
$-2.76M |
|
$-2.76M |
|
$-2.76M |
|
$-2.76M |
|
$-9.21M |
|
$-9.19M |
|
28.70M |
|
28.70M |
|
$-0.10 |
|
$-0.10 |
|
| Balance Sheet Financials | |
$11.57M |
|
$0.06M |
|
$0.23M |
|
$11.80M |
|
$7.84M |
|
-- |
|
$2.54M |
|
$10.39M |
|
$1.41M |
|
$1.41M |
|
$1.41M |
|
28.08M |
|
| Cash Flow Statement Financials | |
$-21.47M |
|
$0.08M |
|
$0.01M |
|
$29.11M |
|
$7.73M |
|
$-21.38M |
|
$1.19M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
1.48 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-21.39M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-195.33% |
|
-195.33% |
|
-23.39% |
|
-195.33% |
|
$0.05 |
|
$-0.75 |
|
$-0.75 |
|